"Investors would have bought this at almost any price," added a Zurich banker.Besides its undisputed name recognition, a range of maturities to access different areas of demand and ratings of A1 (Moodys) and AA- (Fitch), Roche offered significant rarity value. The company last tapped its domestic market back ...
Please take a trial or subscribe to access this content.
Contact Mark Goodes to discuss your access: email@example.com
To discuss GlobalCapital access for your entire department or company please call Mark Goodes on +44 (0)20 7779 8605 or email firstname.lastname@example.org to discuss your requirements.